Quantum Computing Company Surges 57% Today

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

Early Opportunity (Sponsored)

Remember when NASDAQ: OLED launched its IPO at $6 and later soared to a peak of $252.69, achieving a remarkable 4,090% gain?

Now a new MicroLED innovator with a patented groundbreaking technology and a co-development partnership with a major display manufacturer could enable the mass commercialization of MicroLED displays.

Markets 📈

Several U.S. indexes cast aside last week’s market woes, climbing higher today. The Russell 2K saw the most improvement, moving up 1.2% from Friday.

  • DJIA [+0.85%]

  • S&P 500 [+0.64%]

  • Nasdaq [+0.31%]

  • Russell 2K [+1.19%]

Market-Moving News 📈

Food & Beverage

PepsiCo Acquires Poppi in Billion-Dollar Bet on Health-Focused Beverages

PepsiCo (NASDAQ: PEP) has announced its acquisition of prebiotic soda brand Poppi in a deal valued at nearly $2 billion. The move strengthens PepsiCo’s position in the fast-growing functional beverage market, which has gained popularity among health-conscious consumers.

Poppi, known for its apple cider vinegar-based formula and prebiotic benefits, has grown significantly since its launch in 2018. The brand’s success has been fueled by rising consumer demand for alternatives to traditional soft drinks, a trend that has also drawn interest from competitors.

The agreement includes an anticipated $300 million in tax benefits, bringing the net purchase price down. Additional payments could be made if Poppi meets specific performance milestones following the deal's completion. PepsiCo has not disclosed an exact timeline for regulatory approval.

Industry players have been expanding into this space, with Coca-Cola recently launching its prebiotic soda brand. 

Poppi has also gained significant visibility through major marketing efforts, including a Super Bowl advertisement, which helped drive brand awareness. The company's rapid growth has positioned it as a leader in the functional soda category.

Legal challenges have accompanied its expansion, with a recent settlement addressing claims about its health benefits. PepsiCo’s acquisition adds another major brand to its growing portfolio of health-conscious beverage options.

Retail

Walmart’s OnePay Teams Up With Klarna for New Buy Now, Pay Later Service

Walmart (NYSE: WMT) has secured a new partnership with Klarna, making the Swedish fintech firm the exclusive provider of buy now, pay later (BNPL) loans for Walmart shoppers. This move shifts Walmart’s BNPL services from its previous provider, marking a significant step in the retailer’s growing financial technology initiatives.

Customers can access Klarna’s installment payment options in stores and online through Walmart’s fintech subsidiary, OnePay. This new integration will allow shoppers to finance purchases with loan terms ranging from three to 36 months. Klarna will handle underwriting decisions, while OnePay will manage the user experience through its app.

The rollout of this service is expected to begin in the coming weeks, with plans for full integration across Walmart’s platforms by the holiday season. This transition aligns with Walmart’s broader strategy to expand digital payment solutions and enhance financial accessibility for its customers.

Walmart has invested in financial technology to streamline transactions and improve customer convenience. By integrating Klarna’s BNPL offerings, the retailer aims to provide more flexible payment solutions while strengthening its position in the competitive retail finance space.

This development also highlights a shift in Walmart’s approach to digital payments. The company continues expanding its fintech footprint while optimizing its payment ecosystem for millions of shoppers.

The Next Nuclear Boom (Sponsored)

On Behalf of Azincourt Energy Corp


The world’s richest investors—Gates, Bezos, Altman—are pouring billions into nuclear energy. With uranium demand surging, one tiny uranium junior could potentially be the next big winner.

Pharmaceuticals

Incyte Moves Forward with New Skin Condition Treatment Following Trial Data

Incyte (NASDAQ: INCY) has released new data from its latest clinical trial evaluating povorcitinib, an investigational treatment for hidradenitis suppurativa (HS), a chronic inflammatory skin condition.

The Phase III trial results showed that both tested doses of the oral drug met the primary goal of reducing the number of abscesses and inflammatory nodules in patients. The company noted that the safety profile was consistent with previous studies.

Researchers observed that while the drug demonstrated effectiveness, the reduction in symptoms appeared lower than results from earlier trials. Despite this, Incyte reaffirmed plans to proceed with regulatory filings, stating that the findings support its application for approval.

Hidradenitis suppurativa is a difficult-to-treat condition that causes painful skin lesions, and treatment options remain limited. Incyte’s latest trial aims to address the demand for more targeted therapies. The company has been expanding its dermatology portfolio in recent years, seeking to develop advanced treatments for chronic skin diseases.

Incyte’s next steps include submitting povorcitinib for regulatory review while continuing further analysis of the trial data. The company remains focused on advancing its pipeline of dermatological treatments, building on its experience in immunology and inflammation research.

Top Winners and Losers 🔥

Arqit Quantum Inc [ARQQ] $23.54 (+56.93%)

Arqit Quantum benefitted from the surge of investor interest in quantum computing, sending its stock price up.

vTv Therapeutics Inc [VTVT] $22.74 (+53.44%)

vTv Therapeutics enjoyed considerable gains as the FDA lifted its hold on the company’s diabetes drug trial.

Regencell Bioscience Holdings [RGC] $18.50 (+46.59%)

Regencell Bioscience is in good form following a share buyback initiative by the company’s CEO.

USA Rare Earth Inc [USAR] 14.13 (-23.83%)

USA Rare Earth ended its business dealings with Inflection Point Acquisition Corp. II, causing shareholder concern.

Coeptis Therapeutics Holdings [COEP] $8.50 (-23.15%)

Coeptis Therapeutics dropped after only recently securing rights to develop a new cell therapy platform.

Gorilla Technology Group [GRRR] $29.48 (-12.24%)

Gorilla Technology fell on claims from Citron Research that the company is misleading investors.

Technology (Sponsored)

It just signed a deal to get its tech in Apple's iPhone until 2040!

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.